Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. The drop occurred after President Donald Trump suggested that the price for the GLP-1 drug category, which Eli Lilly dominates alongside…
In the latest close session, Eli Lilly (LLY) was up +2.44% at $839.87. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow gained 0.51%, while the tech-heavy Nasdaq lost 0.28%. Heading into today, shares of the drugmaker had gained 10.36% over the past month, outpacing the…
By Andrew Silver SHANGHAI (Reuters) -Innovent Biologics’ newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction. Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo…
Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s (NYSE:LLY) tirzepatide treatment in people with…
Viking Therapeutics (VKTX) stock crashed more than 40% on Tuesday after a phase 2 trial of its weight-loss pill showed a high patient dropout rate. The company stated that most of the adverse treatment-related symptoms were gastrointestinal in nature, and 99% of the adverse events were mild. Over half (58%) of participants taking the drug…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase. The pharmaceutical company announced late-stage trial data for its oral weight-loss pill, orforglipron, which showed an average weight loss of 12.4%. This…
A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. “Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,” said Tony Ren, head…